Abstract
Background Perfusion assessment in cerebrovascular disease is essential for evaluating cerebral hemodynamics and guides many current treatment decisions. Dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) is of great utility to generate perfusion parameter maps, but its reliance on a contrast agent with associated health risks and technical challenges limit its usability. We hypothesized that native Time-of-flight magnetic resonance angiography (TOF-MRA) can be used to generate perfusion parameter maps with an artificial intelligence (AI) method, called generative adversarial network (GAN), offering a contrast-free alternative to DSC-MRI.
Methods We propose an adapted 3D pix2pix GAN that generates common perfusion maps from TOF-MRA images (CBF, CBV, MTT, Tmax). The models are trained on two datasets consisting of 272 patients with acute stroke and steno-occlusive disease. The performance was evaluated by the structural similarity index measure (SSIM), for the acute dataset we calculated the Dice coefficient for lesions with a time-to-maximum (Tmax) >6s.
Findings Our GAN model showed high visual overlap and high performance for all perfusion maps on both the acute stroke dataset (mean SSIM 0.88-092) and data including steno-occlusive disease patients (mean SSIM 0.83–0.98). For lesions of Tmax>6, the median Dice coefficient was 0.49.
Interpretation Our study shows that our AI model can accurately generate perfusion parameter maps from TOF-MRA images, paving the way for clinical utility. We present a non-invasive alternative to contrast agent-based imaging for the assessment of cerebral hemodynamics in patients with cerebrovascular disease. Leveraging TOF-MRA data for the generation of perfusion maps represents a groundbreaking approach in cerebrovascular disease imaging. This method could greatly impact the stratification of patients with cerebrovascular diseases by providing an alternative to contrast agent-based perfusion assessment.
Funding This work has received funding from the European Commission (Horizon2020 grant: PRECISE4Q No. 777107, coordinator: DF) and the German Federal Ministry of Education and Research (Go-Bio grant: PREDICTioN2020 No. 031B0154 lead: DF).
Competing Interest Statement
Dr. Madai reported receiving personal fees from ai4medicine outside the submitted work. Dr. Frey reported receiving grants from the European Commission, reported receiving personal fees from and holding an equity interest in ai4medicine outside the submitted work. While not related to this work, Dr Sobesky reports receipt of speakers honoraria from Pfizer, Boehringer Ingelheim, and Daiichi Sankyo.
Funding Statement
This work has received funding from the European Commission (Horizon2020 grant: PRECISE4Q No. 777107, coordinator: DF) and the German Federal Ministry of Education and Research (Go-Bio grant: PREDICTioN2020 No. 031B0154 lead: DF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the data from Heidelberg, the ethics committee of Heidelberg University gave ethical approval for this work. For the PEGASUS study, the ethics committee of Charite - Universitatsmedizin Berlin gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets presented in this article are not readily available because data protection laws prohibit sharing of the PEGASUS and acute stroke datasets at the current time point. Requests to access these datasets should be directed to the Ethical Review Committee of Charite Universitatsmedizin Berlin, ethikkommission{at}charite.de.
